Alembic's Q1 FY25 Financial Results Show Positive Growth in Sales and Profits

Alembic, a smallcap pharmaceutical company, has recently announced its financial results for the quarter ending March 2024. The company’s stock has been given a ‘Hold’ call by MarketsMOJO, a leading financial analysis platform.

According to the financial report, Alembic has shown a positive performance in the quarter, with a score of 15, which is an improvement from the previous score of 12 in the last 3 months.

One of the key factors contributing to this positive performance is the growth in Profit Before Tax (PBT) less Other Income, which has increased by 95.18% year on year. The near-term trend for PBT is also very positive.

In terms of sales, Alembic has recorded its highest net sales of Rs 50.78 crore in the last five quarters. The near-term trend for sales is also positive, with a growth of 37.84% year on year.

The company’s Profit After Tax (PAT) has also shown a positive growth of 25.8% year on year, with a total of Rs 55.82 crore. The near-term trend for PAT is also positive.

Overall, Alembic’s financial results for the quarter ending March 2024 have been promising, with positive growth in key areas. This is a good sign for the company and its investors, and it will be interesting to see how the company continues to perform in the future.